Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China
Compared to current 1-monthly and 3-monthly formulations, the 6-monthly GnRHa can reduce the total burden associated with prostate cancer treatment.
Authors
- Mengxia Yan
- Jiahua Pan
- Ruiyun Zhang (ORCID: https://orcid.org/0000-0003-3501-646X)
- Bing Wu (ORCID: https://orcid.org/0000-0001-7117-580X)
- Y. Chen (ORCID: https://orcid.org/0009-0001-5955-9410)
- Yan Zhong
Institutions
- China Association for Science and Technology (CN)
- Renji Hospital (CN)
- Ningbo No.6 Hospital (CN)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/ceor.s485856
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Ipsen